Aprea Therapeutics, Inc. (APRE)Healthcare | Biotechnology | Doylestown, United States | NasdaqCM
1.00 USD
+0.09
(10.169%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 0.95 -0.05 (-0.048%) ⇩ (April 17, 2026, 7:33 p.m. EDT) Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 11:28 p.m. EDT
Despite major positive customization headwinds (recent $30M raise, $3T/analyst strong buy recommendations), quant models flag a high-probability short-term downside (-7.8% predicted) due to negative momentum deviation and the stock trading well below its short-term moving averages, indicating poor technical structure regardless of the fundamental catalyst. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.134564 |
| MSTL | 0.134745 |
| AutoTheta | 0.198266 |
| AutoARIMA | 0.248536 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.43 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.517 |
| Excess Kurtosis | -0.84 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.044 |
| Market Cap | 11,452,453 |
| Forward P/E | -1.52 |
| Beta | 1.57 |
| Website | https://aprea.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.3197279 |
| Address1 | 3,805 Old Easton Road |
| All Time High | 1,062.2 |
| All Time Low | 0.474 |
| Ask | 0.9475 |
| Ask Size | 1 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 472,390 |
| Average Daily Volume3 Month | 2,345,288 |
| Average Volume | 2,345,288 |
| Average Volume10Days | 472,390 |
| Beta | 1.574 |
| Bid | 1.0 |
| Bid Size | 1 |
| Board Risk | 6 |
| Book Value | 1.519 |
| City | Doylestown |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.0 |
| Current Ratio | 5.629 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.12 |
| Day Low | 0.9077 |
| Display Name | Aprea Therapeutics |
| Earnings Timestamp End | 1,755,261,000 |
| Earnings Timestamp Start | 1,754,915,400 |
| Ebitda | -13,212,121 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.183 |
| Enterprise To Revenue | -8.467 |
| Enterprise Value | -2,419,534 |
| Eps Current Year | -0.805 |
| Eps Forward | -0.66 |
| Eps Trailing Twelve Months | -1.93 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.77156 |
| Fifty Day Average Change | 0.22843999 |
| Fifty Day Average Change Percent | 0.29607546 |
| Fifty Two Week Change Percent | -31.97279 |
| Fifty Two Week High | 2.22 |
| Fifty Two Week High Change | -1.22 |
| Fifty Two Week High Change Percent | -0.5495496 |
| Fifty Two Week Low | 0.548 |
| Fifty Two Week Low Change | 0.45200002 |
| Fifty Two Week Low Change Percent | 0.8248176 |
| Fifty Two Week Range | 0.548 - 2.22 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,570,109,400,000 |
| Float Shares | 8,780,595 |
| Forward Eps | -0.66 |
| Forward P E | -1.5151515 |
| Free Cashflow | -8,564,504 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 8 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.0 |
| Gross Profits | -6,757,276 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.12494001 |
| Held Percent Institutions | 0.14807001 |
| Implied Shares Outstanding | 11,452,453 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,676,246,400 |
| Last Split Factor | 1:20 |
| Long Business Summary | Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania. |
| Long Name | Aprea Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 11,452,453 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_329831339 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -12,599,569 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 11,796,025 |
| Number Of Analyst Opinions | 3 |
| Open | 0.9077 |
| Operating Cashflow | -12,894,439 |
| Operating Margins | -792.05664 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 215 948 4119 |
| Post Market Change | -0.047699988 |
| Post Market Change Percent | -4.7699986 |
| Post Market Price | 0.9523 |
| Post Market Time | 1,776,468,828 |
| Previous Close | 0.9077 |
| Price Eps Current Year | -1.242236 |
| Price Hint | 4 |
| Price To Book | 0.6583278 |
| Price To Sales Trailing12 Months | 40.077312 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.281 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | 0.0923 |
| Regular Market Change Percent | 10.1686 |
| Regular Market Day High | 1.12 |
| Regular Market Day Low | 0.9077 |
| Regular Market Day Range | 0.9077 - 1.12 |
| Regular Market Open | 0.9077 |
| Regular Market Previous Close | 0.9077 |
| Regular Market Price | 1.0 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 1,127,288 |
| Return On Assets | -0.41446 |
| Return On Equity | -0.74581003 |
| Revenue Growth | -0.984 |
| Revenue Per Share | 0.044 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 11,452,452 |
| Shares Percent Shares Out | 0.0559 |
| Shares Short | 640,347 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 245,983 |
| Short Name | Aprea Therapeutics, Inc. |
| Short Percent Of Float | 0.059299998 |
| Short Ratio | 1.16 |
| Source Interval | 15 |
| State | PA |
| Symbol | APRE |
| Target High Price | 7.0 |
| Target Low Price | 1.2 |
| Target Mean Price | 4.4 |
| Target Median Price | 5.0 |
| Total Cash | 14,599,347 |
| Total Cash Per Share | 1.275 |
| Total Debt | 0 |
| Total Revenue | 285,759 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.93 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.19978 |
| Two Hundred Day Average Change | -0.19977999 |
| Two Hundred Day Average Change Percent | -0.16651385 |
| Type Disp | Equity |
| Volume | 1,127,288 |
| Website | https://aprea.com |
| Zip | 18,902 |